Metachromatic Leukodystrophy: Diagnosis, Treatment, Information

Introduction

Metachromatic Leukodystrophy Alternate Names: Arylsulfatase A Deficiency (ARSA), Cerebroside Sulfatase Deficiency, Metachromatic Form of Diffuse Cerebral Sclerosis, Metachromatic Leukoencephalopathy, Scholz-Bielchowsky-Henneberg Diffuse Cerebral Sclerosis, Scholz-Greenfield Disease, Sulphatide Lipidosis, Sulphatidosis, Van Bogaert-Nijssen Disease

The U.S. Social Security Administration (SSA) has included Metachromatic Leukodystrophy (MLD) - Late Infantile as a Compassionate Allowance to expedite a disability claim.

Main Digest

MLD impairs the growth or development of the myelin sheath, the fatty covering that acts as an insulator around nerve fibers.

Late infantile form, the most common MLD, usually begins in the second year of life (ranges 1-3 years). After normal early development, the infant displays irritability and unstable walking. Developmental milestones, such as language development, are not met, and muscle wasting eventually leads to spastic movements, then profound weakness. Seizures usually occur, followed by paralysis and dementia. Children may become comatose.

Diagnosis of MLD includes MRI to identify lesions and atrophy in the brain's white matter characteristic of MLD. Urine tests usually show elevated sulfatide levels. Some psychiatric disorders coupled with difficulty walking or muscle wasting suggest the possibility of MLD. Blood testing can show the reduced activity of the ARSA enzyme.

Deficiency of the ARSA enzyme alone is not proof of MLD because a substantial ARSA deficiency without any symptoms or clinical consequences is frequent in the general population. During diagnosis and genetic counseling, these harmless ARSA enzyme deficiencies must be distinguished from those causing MLD. The only diagnostic test that solves this problem and is definitive for MLD diagnosis is an analysis of the genetic mutation.

No effective treatment is available to reverse the course of MLD. Drug therapy is part of supportive care for symptoms such as behavioral disturbances, feeding difficulties, seizures, and constipation. Bone marrow transplantation has been tried, and there is evidence that this treatment might slow the progression of the disease. In infants, during a symptom-free phase of the late infantile form, the neurocognitive function may be stabilized, but the symptoms of motor function loss progress.

The prognosis for MLD is poor. In young children with MLD late infantile form, progressive loss of motor and cognitive functions is rapid. Death usually results within five years after the onset of clinical symptoms.

Related Publications▶ Share This Page

Page Information, Citing and Disclaimer

Disabled World is a comprehensive online resource that provides information and news related to disabilities, assistive technologies, and accessibility issues. Founded in 2004 our website covers a wide range of topics, including disability rights, healthcare, education, employment, and independent living, with the goal of supporting the disability community and their families.

Cite This Page (APA): Langtree, I. C. (2009, April 4 - Last revised: 2023, January 31). Metachromatic Leukodystrophy: Diagnosis, Treatment, Information. Disabled World. Retrieved September 11, 2024 from www.disabled-world.com/health/pediatric/metachromatic-leukodystrophy.php

Permalink: <a href="https://www.disabled-world.com/health/pediatric/metachromatic-leukodystrophy.php">Metachromatic Leukodystrophy: Diagnosis, Treatment, Information</a>: Metachromatic leukodystrophy (MLD) is a hereditary degenerative disease transmitted as an autosomal recessive due to sulfatase, a deficiency with excess accumulation of sulfated lipids responsible for metachromasia in various tissues.

Disabled World provides general information only. Materials presented are never meant to substitute for qualified medical care. Any 3rd party offering or advertising does not constitute an endorsement.